BIOLOGICAL TUMOR SUBTYPE AS A BASIS OF ADJUVANT TREATMENT OF MALE BREAST CANCER
https://doi.org/10.18027/2224-5057-2016-1-10-16
Abstract
Male breast cancer (MBC), is very rare disease in spite of the women’s. That is why it has not been thoroughly investigated in terms of transcriptional profiles or genomic aberrations.. Most of our understanding of MBC has therefore been extrapolated from knowledge of female breast cancer. The same prognostic and predictive markers are used to determine optimal management strategies for both men and women diagnosed with breast cancer. This article is focused on prognosis for MBC patients, prognostic and predictive factors and molecular subgrouping. Information was collected from 2000 till 2014 y. about 84 men with the breast cancer. We could not found the HER2-neu biological type of the tumour and combine all patients for two groups: Luminal A and Non luminal A. All patients were treated by chemotherapy, hormonotherapy or combination chemohormonotherapy. No advantages were found in the Luminal A subtype between hormonotherapy and combination chemohormonotherapy but in the Nonluminal A subtype 5 y. overall survival were better when the patients were treated by combination of chemotherapy and hormonotherapy.
About the Authors
K. S. Nikolaev
Research Institute of oncology named after N.N. Petrov. Breast cancer department. St. Petersburg
Russian Federation
Russian Federation
candidate of medical sciences, oncologist
V. F. Semiglazov
Research Institute of oncology named after N.N. Petrov. Breast cancer department
Russian Federation
Russian Federation
doctor of medicine, oncologist, chair of the breast cancer department.
V. G. Ivanov
North-Western State Medical University named after I. I. Mechnikov. Plastic and reconstruction surgery department
Russian Federation
Russian Federation
candidate of medical sciences, oncologist. Research Institute of oncology named after N.N. Petrov. Breast cancer department. St. Petersburg
E. K. Ziltsova
Research Institute of oncology named after N.N. Petrov. Breast cancer department. St. Petersburg
Russian Federation
Russian Federation
candidate of medical sciences, oncologist
O. A. Ivanova
Research Institute of oncology named after N.N. Petrov. Breast cancer department. St. Petersburg
Russian Federation
candidate of medical sciences, oncologist
Russian Federation
candidate of medical sciences, oncologist
References
1. Аксель Е.М. Злокачественные новообразования молочной железы: состояние онкологической помощи, заболеваемость и смертность. // Маммология.– 2006. – № 1. – c.9. Aksel EM. Malignant tumors of the breast: the state of cancer care, morbidity and mortality. // Mammalogy. – 2006. – № 1. – p.9.
2. Мерабишвили В.М. Выживаемость онкологических больных. Выпуск второй. Часть 1. // СПб. – 2011. – 350 с. Merabishvili VM. The survival rate of cancer patients. Second Edition. Part 1. // SPb. – 2011. – 350 p.
3. Мерабишвили В.М. Онкологическая статистика. Руководство для врачей. Часть II. – СПб.– 2011. – 248 с. Merabishvili VM. Cancer statistics. Guide for physicians. Part II. – SPb. – 2011. – 248 p.
4. Giordano SH, Cohen DS, Buzdar AU et al. Breast carcinoma in men: a population-based study. Cancer 2004; 101:51–57.
5. Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol 2010; Vol.28: pp.232–9.
6. Donegan WL, Redlich PN, Lang PJ, Gall MT. Carcinoma of the breast in males: a multiinstitutional survey. Cancer 1998; Vol.83: pp.498–509.
7. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000; Vol.406: pp.747–52.
8. J nsson G, Staaf J, Vallon-Christersson J, Ringner M, Holm K, Hegardt C, et al. Genomic subtypes of breast cancer identified by array comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 2010; Vol.12: p.R42.
9. Speirs V, Ball G, Male Breast Cancer Consortium. Male versus female breast cancer: a comparative study of 523 matched cases reveals differences behind similarity. Breast Cancer Res 2010; Vol.12(Suppl.1): p.01.
10. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; Vol.98: pp.10869–74.
11. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003; Vol.100: pp.10393–10398.
12. Семиглазов В.Ф., Семиглазов В.В., Дашян Г.А., Палтуев Р.М., Мигманова Н.Ш., Щедрин Д. Е., Гречухина И.А., Бессонов А.А., Пеньков К.Д., Мерабишвили В.М. Рак молочной железы у мужчин. // Фарматека.– 2010. – № 6. – Т. 200. – с. 40–45. Semiglazov VF, Semiglazov VV, Dashyan GA, Paltuev RM, Migmanova NS, Shchedrin DE, Grechukhina IA, Bessonov AA, Penkov KD, Merabishvili VM. Male breast cancer. // Farmateka.– 2010. – № 6. – Vol. 200. – pp. 40–45.
13. Семиглазов В.Ф., Семиглазов В.В., Клецель А.Е. Рак молочной железы у мужчин. // Неинвазивные и инвазивные опухоли молочной железы. СПб.– 2006. – с. 288–299. Semiglazov VF, Semiglazov VV, Kletsel AE. Male breast cancer. // Non-invasive and invasive breast tumors. Spb. – 2006. – pp. 288–299.
14. Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001; Vol.182: pp.389–92.
15. Николаев К.С., Семиглазов В.Ф. Рак молочной железы у мужчин. Глава в книге. Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы. Биология, местное и системное лечение. – М.: СИМК, – 2014. – 298–341 с. Nikolaev KS, Semiglazov VF. Male breast cancer. A chapter in the book. Semiglazov VF, Semiglazov VV. Breast cancer. Biology, local and systemic treatment. – M.: SIMK, – 2014. – 298–341 p.
16. Николаев К.С., Семиглазов В.Ф., Семиглазов В.В. Рак молочной железы у мужчин (обзор литературы). // Современная онкология. – 2014. – № 4. – Т. 16. – 31–37 c. Nikolaev KS, Semiglazov VF, Semiglazov VV. Male breast cancer (review). // Sovremennaya oncologiya.– 2014.– № 4.– Vol. 16.– pp.31–37.
Review
For citations:
Nikolaev K.S., Semiglazov V.F., Ivanov V.G., Ziltsova E.K., Ivanova O.A. BIOLOGICAL TUMOR SUBTYPE AS A BASIS OF ADJUVANT TREATMENT OF MALE BREAST CANCER. Malignant tumours. 2016;(1):10-16. (In Russ.) https://doi.org/10.18027/2224-5057-2016-1-10-16
Views:
2091
Email this article 